Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
123.3 USD | +5.01% | -5.04% | +27.89% |
Jun. 03 | Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 1000 | CI |
Jun. 03 | Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 400 - Biotechnology | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's enterprise value to sales, at 5.47 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.89% | 11.66B | C+ | ||
+18.72% | 125B | B+ | ||
+14.19% | 108B | B+ | ||
-4.93% | 24.21B | B+ | ||
+1.19% | 22.78B | B | ||
-11.28% | 17.96B | A- | ||
-41.74% | 16.43B | A- | ||
-13.31% | 16.37B | B | ||
+2.44% | 13.58B | C+ | ||
+83.45% | 9.17B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SRPT Stock
- Ratings Sarepta Therapeutics, Inc.